News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Moxie Dwight
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/15/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 19,346 shares
@ $0 Paid exercise price by delivering 9,592 shares
@ $18.91, valued at
$181.4k
|
|
05/16/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 42,349 shares
@ $0 Sold 21,401 shares
@ $34.5469, valued at
$739.3k
|
|
03/17/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Paid exercise price by delivering 7,330 shares
@ $30.65, valued at
$224.7k
|
|
03/09/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 42,349 shares
@ $0 Sold 18,496 shares
@ $31.5863, valued at
$584.2k
|
|
02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/16/2022 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Sold 11,000 shares
@ $27.0725, valued at
$297.8k
|
|
03/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/04/2022 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 68,093 options to buy
@ $13.08, valued at
$890.7k
|
|
09/28/2021 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Sold 1,675 shares
@ $30, valued at
$50.3k
|
|
03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/02/2020 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.
Txns:
| Granted 12,250 shares
@ $0 Paid exercise price by delivering 4,236 shares
@ $25.14, valued at
$106.5k
|
|
02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|